Sight Sciences (NASDAQ: SGHT) insider transactions
In the twelve months to 10 November 2026, executives and directors of Sight Sciences reported 38 open-market sales of 440,806 shares ($2.9m) and 2 open-market purchases of 28,058 shares ($184,799), by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 2 October 2026 | Rodberg James | Chief Financial Officer | Open-market sale, 10b5-1 plan | −7,208 | $8.85 | 216,829 | Form 4 |
| 2 October 2026 | Bauerlein Alison | Chief Operating Officer | Open-market sale, 10b5-1 plan | −25,260 | $8.85 | 639,449 | Form 4 |
| 2 October 2026 | Taylor Brenton | EVP, Operations & R&D | Open-market sale, 10b5-1 plan | −2,988 | $8.85 | 261,990 | Form 4 |
| 1 October 2026 | Badawi Paul | President and CEO | Open-market sale, 10b5-1 plan | −29,653 | $9.05 | 6,092,819 | Form 4 |
| 1 October 2026 | Badawi David | Chief Technology Officer | Open-market sale, 10b5-1 plan | −7,797 | $9.05 | 1,975,075 | Form 4 |
| 10 August 2026 | Rashid Kashif | Chief Legal Officer | Grant or award | +181,818 | — | 181,818 | Form 4 |
| 6 July 2026 | Badawi David | Chief Technology Officer | Open-market sale | −7,418 | $5.51 | 1,982,872 | Form 4 |
| 6 July 2026 | Hayden Jeremy B. | Chief Legal Officer | Open-market sale | −12,733 | $5.51 | 357,037 | Form 4 |
| 2 July 2026 | Bauerlein Alison | Chief Operating Officer | Open-market sale | −24,184 | $5.36 | 664,709 | Form 4 |
| 2 July 2026 | Rodberg James | Chief Financial Officer | Open-market sale | −6,902 | $5.36 | 224,037 | Form 4 |
| 1 July 2026 | Badawi Paul | President and CEO | Open-market sale | −28,684 | $5.42 | 6,122,472 | Form 4 |
| 1 July 2026 | Taylor Brenton | EVP, Operations & R&D | Open-market sale | −2,829 | $5.42 | 264,978 | Form 4 |
| 10 June 2026 | Encrantz Staffan | Director | Open-market purchase | +14,100 | $4.88 | 1,434,283 | Form 4 |
| 4 June 2026 | Mazzacco Catherine | Director | Grant or award | +28,261 | — | 69,276 | Form 4 |
| 4 June 2026 | Zurbay Donald | Director | Grant or award | +28,261 | — | 193,613 | Form 4 |
| 4 June 2026 | Burbach Gerhard F | Director | Grant or award | +28,261 | — | 123,207 | Form 4 |
| 4 June 2026 | Encrantz Staffan | Director | Grant or award | +28,261 | — | 1,420,183 | Form 4 |
| 4 June 2026 | Fountain Tamara | Director | Grant or award | +28,261 | — | 109,650 | Form 4 |
| 18 May 2026 | Bauerlein Alison | Chief Operating Officer | Open-market sale | −12,728 | $5.12 | 688,893 | Form 4 |
| 6 April 2026 | Hayden Jeremy B. | Chief Legal Officer | Open-market sale | −13,761 | $3.55 | 369,770 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Sight Sciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.